OVID Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
733.0K
0
-100.0%
718.0K
+443.9%
132.0K
-97.9%
6.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
733.0K
0
-100.0%
718.0K
+443.9%
132.0K
-97.9%
6.3M
Operating Expenses
16.4M
-7.9%
17.8M
+37.2%
13.0M
+2.8%
12.7M
+11.5%
11.3M
R&D
10.0M
-10.9%
11.2M
+69.7%
6.6M
+12.2%
5.9M
-9.2%
6.5M
SG&A
6.5M
-2.9%
6.7M
+3.8%
6.4M
-5.4%
6.8M
+39.0%
4.9M
Operating Income
-15698000
+12.0%
-17846000
-45.2%
-12293000
+1.8%
-12523000
-146.9%
-5073000
EBITDA
-15682000
+12.0%
-17811000
-45.1%
-12276000
+1.8%
-12507000
-151.4%
-4974000
Net Income
-15009000
+11.6%
-16988000
-275.8%
9.7M
+179.5%
-12158000
-159.6%
-4684000
EPS (Basic)
$-0.08
+33.3%
$-0.12
-200.0%
$0.12
+170.6%
$-0.17
-183.3%
$-0.06
EPS (Diluted)
$-0.08
+33.3%
$-0.12
-200.0%
$0.12
+170.6%
$-0.17
-183.3%
$-0.06
Shares (Diluted)
197.5M
+45.0%
136.2M
+66.7%
81.7M
+14.8%
71.1M
+0.0%
71.1M
Ovid Therapeutics (OVID) โ€” Financials